The Technical Analyst
RxSight, Inc. [RXST]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
RxSight, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.33% $51.58
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 907.82 mill |
| EPS: | -1.410 |
| P/E: | -36.58 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 36.99 mill |
| Avg Daily Volume: | 0.406 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -36.58 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.16x |
| Company: PE -36.58 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 49.16 - 54.00 ( +/- 4.69%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Thunen Shelley B | Sell | 8 857 | Common Stock |
| 2024-04-01 | Thunen Shelley B | Sell | 800 | Common Stock |
| 2024-04-01 | Thunen Shelley B | Sell | 8 938 | Common Stock |
| 2024-04-01 | Thunen Shelley B | Sell | 662 | Common Stock |
| 2024-04-01 | Thunen Shelley B | Sell | 200 | Common Stock |
| INSIDER POWER |
|---|
| 5.75 |
| Last 100 transactions |
| Buy: 649 170 | Sell: 601 875 |
Forecast:
16:00 - $51.60
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $51.60
Forecast 2: 16:00 - $51.60
Forecast 3: 16:00 - $51.60
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $51.58 (-0.33% ) |
| Volume | 0.233 mill |
| Avg. Vol. | 0.406 mill |
| % of Avg. Vol | 57.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RXST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $48.74 | N/A | Active |
|---|
RXST
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Latest Press Releases
2024-04-04 16:05:00 - Press Release
Rxsight Announces Commercial Launch Of Its Newest Light Adjustable Lens™, The Lal+™, And Features Multiple Doctor Presentations At The Upcoming Ascrs Annual Meeting
Aliso viejo, calif., april 04, 2024 (globe newswire) -- (nasdaq: rxst) – rxsight, inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest light adjustable lens, the lal+. the company now offers two lenses in the light adjustable lens platform: the lal® and the light adjustable lens+™ (lal+). the lal+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
2024-03-27 16:05:00 - Press Release
Rxsight, Inc. To Participate In The 23rd Annual Needham Virtual Healthcare Conference
Aliso viejo, calif., march 27, 2024 (globe newswire) -- (nasdaq: rxst) rxsight, inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 23rd annual needham virtual healthcare conference.
2024-02-29 19:05:00 - Press Release
Rxsight, Inc. To Participate In The 34th Annual Oppenheimer Healthcare Conference
Aliso viejo, calif., feb. 29, 2024 (globe newswire) -- (nasdaq: rxst) rxsight, inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 34th annual oppenheimer healthcare conference.
2024-02-28 16:05:00 - Press Release
Rxsight, Inc. Reports Fourth Quarter And Full Year 2023 Financial Results
Aliso viejo, calif., feb. 28, 2024 (globe newswire) -- rxsight, inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended december 31, 2023.
2024-02-14 16:05:00 - Press Release
Rxsight, Inc. To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024
Aliso viejo, calif., feb. 14, 2024 (globe newswire) -- (nasdaq: rxst) - rxsight, inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on wednesday, february 28, 2024. the company's management will discuss the results during a conference call beginning at 1:30 p.m. pacific time / 4:30 p.m. eastern time.
Latest News
2024-02-28 23:44:04 - Seeking Alpha
RxSight, Inc. (RXST) Q4 2023 Earnings Call Transcript
2024-02-14 16:05:00 - GlobeNewsWire
RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Wednesday, February 28, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
2024-01-12 15:16:56 - InvestorPlace
3 Stocks to Buy BEFORE They Become Household Names
Steve Symington is a long-time contributor to The Motley Fool. Over the years, he's written more than 8,000 articles for the publication.
2023-12-27 16:05:00 - GlobeNewsWire
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.
2023-11-12 04:19:02 - Seeking Alpha
RxSight, Inc. (RXST) Q3 2023 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, Investor Relations Ron Kurtz - President and Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Joseph Conway - Needham & Co Rohin Patel - JPMorgan Steven Lichtman - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the RxSight Third Quarter 2023 Earnings Call.
2023-10-27 11:12:40 - Seeking Alpha
RxSight: Losing Altitude Despite 'Best Of Breed' Platform
Today we look at RxSight, Inc., a small ocular focused medical device company focused on transforming the cataract surgery market. The company is delivering 70% year-over-year revenue growth and rapidly expanding its installed base. After a big rally early this summer, the stock has given up a third of its value during the overall selloff in the market that began in August.
2023-10-23 11:52:25 - Seeking Alpha
Trading The Top-Performing AI Companies From The Small Cap Universe
Small-cap tech stocks have been overshadowed by mega-cap tech giants despite their potential for innovation and future growth. Smaller-cap stocks have appeal for potential acquisition by larger corporations. Three small cap tech stocks focused on AI—Applied Digital (APLD), Innodata (INOD) and Rigetti (RGTI)—are especially intriguing looking ahead into 2024.
2023-09-07 11:17:34 - Zacks Investment Research
RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors
After reaching an important support level, RxSight, Inc. (RXST) could be a good stock pick from a technical perspective. RXST surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
2023-08-23 16:05:00 - GlobeNewsWire
RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference.
2023-08-07 19:39:09 - Zacks Investment Research
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.50 per share a year ago.